Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 5/20 | 0.40 |
| ▸ | AKT1 | P31749 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 6/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3889725 | 0.88 | HTR2C (0.47) | RPS6KB1AKT1HTR2CFLT3HRH3 | |
| Trifluoroacetic Acid SCHEMBL3882180 | 0.84 | FLT3 (0.54) | FLT3 | |
| Trifluoroacetic Acid SCHEMBL6749589 | 0.77 | NEK2 (0.54) | HTR2CHRH4ADORA2AEPHX2HRH3 | |
| SCHEMBL3884555 | 0.77 | FLT3 (0.44) | RPS6KB1AKT1FLT3 | |
| Trifluoroacetic Acid SCHEMBL2794605 | 0.72 | AKT1S1 (0.47) | HTR2CHRH4EPHX2HRH3 | |
| Trifluoroacetic Acid SCHEMBL4963337 | 0.71 | FLT3 (0.52) | RPS6KB1FLT3 | |
| Trifluoroacetic Acid SCHEMBL2421451 | 0.71 | CYP2D6 (0.45) | HRH4EPHX2HRH3 | |
| SCHEMBL14596991 | 0.70 | BTK (0.44) | AKT1FLT3 | |
| Trifluoroacetic Acid SCHEMBL30484802 | 0.70 | KDM4E (0.43) | HRH4ADORA2AHRH3 | |
| SCHEMBL13956850 | 0.69 | FLT3 (0.55) | HTR2CFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1898917-B1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-01-14 | — | — | EP | disclosed |
| EP-1901745-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1898917-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| US-20070021435-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| WO-2006135719-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135713-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281755-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | BAUMANN CHRISTIAN A | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021435-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | FLT3, KIT, TK1 | RPS6KB1 220/4885AKT1 224/4885HTR2C 1885/4885 |
| US-20060281755-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | FLT3, CSF3R, CSF1R | RPS6KB1 181/4885AKT1 182/4885HTR2C 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.